Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B

Amphotericin B deoxycholate (AMB) has substantial toxicities. A novel encochleated amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal model, and minimal toxicity due to targeted drug delivery into macrophages, where intracellular fungi reside. We conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Skipper, Caleb P., Atukunda, Mucunguzi, Stadelman, Anna, Engen, Nicole W., Bangdiwala, Ananta S., Hullsiek, Katherine H., Abassi, Mahsa, Rhein, Joshua, Nicol, Melanie R., Laker, Eva, Williams, Darlisha A., Mannino, Raphael, Matkovits, Theresa, Meya, David B., Boulware, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508607/
https://www.ncbi.nlm.nih.gov/pubmed/32747357
http://dx.doi.org/10.1128/AAC.00838-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508607/
https://www.ncbi.nlm.nih.gov/pubmed/32747357
http://dx.doi.org/10.1128/AAC.00838-20

Ejemplares similares